Photo of Matthew Hiram Taylor, MD

Matthew Hiram Taylor MD

Dr. Taylor specializes in phase I clinical trials for patients with advanced cancers. He has a particular interest in thyroid cancers. In addition to his clinical research, Dr. Taylor studies cancer cells and patients tumors in his laboratory.Dr. Taylor and his wife Jessica, are the proud parents of four daughters. When he is not at the hospital, he is at soccer games, piano recitals, ballet and dance performances, and school plays. When there’s time, he enjoys cycling, golf, and oddly enough – yard work.


  • M.D., Oregon Health & Science University, Portland Oregon 0 2005
  • Residency:

    • Internal medicine, University of Washington, 2007
  • Fellowship:

    • Hematology and medical oncology, Oregon Health & Science University, 2010
  • Certifications:

    • American Board of Internal Medicine, 2009

Memberships and associations

  • American College of Physicians


  • "Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor) : pooled results from two expansion cohorts of an open-label, phase 1 trial." The Lancet Oncology In: , Vol. 19, No. 1, 01.01.2018, p. 51-64.
  • "Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors." Journal of Clinical Oncology  In: , Vol. 35, No. 18, 20.06.2017, p. 2028-2036.
  • "Academic cancer center phase i program development." Oncologist In: , Vol. 22, No. 4, 01.04.2017, p. 369-374.
  • "Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer." Journal of Clinical Endocrinology and Metabolism  In: , Vol. 101, No. 11, 01.11.2016, p. 4103-4109.
  • "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma : 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial." The Lancet Oncology In: , Vol. 17, No. 11, 01.11.2016, p. 1558-1568.
  • "Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors." Cancer  In: , Vol. 122, No. 16, 15.08.2016, p. 2524-2533.
  • "Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer." Cancer Management and Research In: , Vol. 8, 30.05.2016, p. 67-76.
  • "Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032) : A multicentre, open-label, phase 1/2 trial." The Lancet Oncology  In: , 2016.
  • "Fibroblast Growth Factor Signaling Controls Liver Size in Mice with Humanized Livers." Gastroenterology  In: , Vol. 149, No. 3, 01.09.2015, p. 728e15-740e15.
  • "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma." New England Journal of Medicine  In: , Vol. 372, No. 21, 21.05.2015, p. 2006-2017.
  • "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer." New England Journal of Medicine In: , Vol. 372, No. 7, 12.02.2015, p. 621-630.
  • "Medical Therapy for Advanced Forms of Thyroid Cancer." Surgical Clinics of North America  In: , Vol. 94, No. 3, 2014, p. 541-571.
  • "The ploidy conveyor of mature hepatocytes as a source of genetic variation." Nature  In: , Vol. 467, No. 7316, 07.10.2010, p. 707-710.

Additional information

Edit profile